Series A · Biotech · Cambridge, United Kingdom · Founded 2016 · 11–50 employees
Camena Bioscience is a synthetic biology company that has developed a revolutionary enzymatic DNA synthesis technology called gSynth®, which enables the production of long and complex gene sequences with superior accuracy compared to traditional methods. The company serves pharmaceutical, agriculture, and diagnostics customers with their DNA synthesis solutions, addressing critical limitations of existing DNA synthesis methods. They closed a $10M Series A round led by Mercia Ventures in July 2023 and have secured commercial agreements with leading consumers of synthetic genes. Their technology is particularly valuable for enabling mRNA vaccine development and complex antibody engineering, positioning them at the forefront of the synthetic biology revolution.
No open roles listed right now.